Related Experiment Video
Updated: Jan 15, 2026
08:33
Targeting Alpha Synuclein Aggregates in Cutaneous Peripheral Nerve Fibers by Free-floating Immunofluorescence Assay
Published on: June 25, 2019
8.6K
Multi-Fused S,N-Heterocyclic Compounds for Targeting α-Synuclein Aggregates
Chao Zheng1, Jeffrey S Stehouwer2, Goverdhan Reddy Ummenthala3
1MedChem Imaging, Inc., Boston, MA 02210, USA.
Cells
|October 15, 2025
Summary
Developing new positron emission tomography (PET) tracers for alpha-synuclein (α-syn) aggregates is crucial for diagnosing synucleinopathies like Parkinson's disease. This study presents novel S,N-heterocyclic compounds as promising PET tracer candidates for improved diagnosis and treatment.
Area of Science:
- Neuroscience
- Radiochemistry
- Molecular Imaging
Background:
- Positison emission tomography (PET) tracers targeting alpha-synuclein (α-syn) aggregates are vital for diagnosing synucleinopathies, including Parkinson's disease (PD), dementia with Lewy bodies (DLB), and multiple system atrophy (MSA).
- Challenges in developing α-syn PET tracers include low aggregate abundance, structural heterogeneity, co-pathology, and poor metabolic stability, hindering progress.
- Optimizing existing tracers like [18F]asyn-44 is essential for advancing diagnostic and therapeutic strategies for these neurodegenerative diseases.
Purpose of the Study:
- To synthesize and evaluate novel S,N-heterocyclic scaffold derivatives as potential PET tracers for α-syn aggregates.
- To overcome existing limitations in α-syn PET tracer development by improving potency and metabolic stability.
- To provide advanced molecular tools for synucleinopathies and guide clinical trials.
Main Methods:
- Synthesis of a library of 49 novel S,N-heterocyclic compounds.
- Evaluation of compound potency using equilibrium inhibition constants (Ki) in Parkinson's disease brain homogenates.
- Assessment of radiolabeling potential with fluorine-18 for PET imaging.
Main Results:
- Identified 8 potent S,N-heterocyclic derivatives (LMD-006, LMD-022, LMD-029, LMD-044, LMD-045, LMD-046, LMD-051, and LMD-052) with Ki values ranging from 6-16 nM.
- All identified derivatives demonstrated amenability for radiolabeling with fluorine-18.
- These novel compounds represent significant advancements over previous pyridothiophene-based tracers.
Conclusions:
- The developed S,N-heterocyclic compounds show high affinity for α-syn aggregates and are suitable for radiolabeling.
- These novel tracers offer a promising molecular toolkit for the diagnosis and management of synucleinopathies.
- The findings provide a roadmap for overcoming barriers in PET tracer development and support biomarker-guided clinical trials.
